Comparison of intravenous ceftriaxone and ciprofloxacin in prevention of infection in cirrhosis patients with variceal bleeding


  • Ram Dev Chaudhary Department of Medicine, Gastroenterology Unit, Mayo Hospital, Lahore, Pakistan
  • Ommar Jamil Department of Medicine, Gastroenterology Unit, Mayo Hospital, Lahore, Pakistan
  • Sandeep Raj Kunwar Department of Medicine, Gastroenterology Unit, Mayo Hospital, Lahore, Pakistan
  • M. Ayub Department of Medicine, Gastroenterology Unit, Mayo Hospital, Lahore, Pakistan
  • Shahid Sarwar Department of Medicine, Gastroenterology Unit, Mayo Hospital, Lahore, Pakistan
  • Tahira Murtaza Cheema Department of Medicine, Gastroenterology Unit, Mayo Hospital, Lahore, Pakistan



Variceal bleeding, Liver cirrhosis, Antibiotics, Infection, Sepsis


Background: Patients with variceal gastrointestinal bleeding are very susceptible to bacterial infections. This study was designed to examine the effectiveness of ciprofloxacin and ceftriaxone in controlling in-hospital morbidity, mortality, and infection in variceal bleeding patients.

Methods: From August 2010 to August 2012, an interventional randomized controlled clinical trial was conducted in the Department of Gastroenterology, East Medical Ward, Mayo Hospital, Lahore. Adult patients who were diagnosed to have gastroesophageal variceal bleeding after endoscopic examination were included. These patients were randomly distributed to 2 groups. Group ceftriaxone: receiving injection Ceftriaxone 1000 mg intravenously 12 hourly for 7 days, Group ciprofloxacin: receiving injection ciprofloxacin 200 mg intravenously 12 hourly for 7 days.

Results: Most common viral etiology was Hepatitis C in both the study groups. It was observed that in the ceftriaxone group, 4.8% had rebleeding, while in the ciprofloxacin group 5.6% had rebleeding (p=0.77), one case each had porto-systemic encephalopathy (p=0.99), 0.8% in ceftriaxone group and 3.2% in ciprofloxacin group had spontaneous bacterial peritonitis (p=0.39) and 4.8% in ceftriaxone group and 8% in ciprofloxacin group had systemic inflammatory response syndrome (p=0.31). No patients died during one week follow up.

Conclusions: From our study, it was concluded that ciprofloxacin and ceftriaxone had same efficacy when used intravenously for prevention of bacterial infection and improvement in mortality and morbidity in patient of variceal bleeding. Future multicentric studies are required with a longer patient follow to support our findings.


Moon AM, Dominitz JA, Ioannou GN, Lowy E, Beste LA. Use of antibiotics among patients with cirrhosis and upper gastrointestinal bleeding Is associated with reduced mortality. Clin Gastroenterol Hepatol. 2016;v14(11):1629-37.

Scaglione S, Kliethermes S, Cao G, Shoham D, Durazo R, Luke A, et al. The epidemiology of cirrhosis in the United States: a population-based study. J Clin Gastroenterol. 2015;49(8):690-6.

Hilzenrat N, Averell HS. Esophageal varices: pathophysiology, approach, and clinical dilemmas. Int J Hepatol. 2012;2012:1.

Garcia-Tsao G, Abraldes J, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2017;65:1.

Kovalak M, Lake J, Mattek N, Eisen G, Lieberman D, Zaman A. Endoscopic screening for varices in cirrhotic patients: data from a national endoscopic database. Gastrointes Endos. 2007;65(1):82-8.

Goulis J, Armonis A, Patch D, Sabin C, Greenslade L, Burroughs AK. Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage. Hepatology. 1998;27:1207-12.

Tripathi D, Stanley A, Hayes P, Patch D, Millson C, Mehrzad H, et al. UK guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut. 2015;64:1680-704.

Huang X, Liu C, Li F, Chen S. Rifaximin has no effect on rebleeding in cirrhotic portal hypertension an open-label- randomized controlled trial. Gastroenterology. 2018;154(6):1252.

Rimola A, Garcia-Tsao G, Navasa M, Piddock LJ, Planas R, Ber- nard B, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. Inter- national Ascites Club. J Hepatol. 2000;32:142-53.

Aparicio JR, Such J, Pascual S, Arroyo A, Plazas J, Girona E, et al. Development of quinolone-resistant strains of Escherichia coli in stools of patients with cirrhosis undergoing norfloxacin prophy- laxis: clinical consequences. J Hepatol. 1999;31:277-83.

Novella M, Solà R, Soriano G, Andreu M, Gana J, Ortiz J, et al. Continuous versus inpatient prophylaxis of the first episode of spontaneous bacte- rial peritonitis with norfloxacin. Hepatology. 1997;25:532-6.

Hsieh WJ, Lin HC, Hwang SJ, Hou MC, Lee FY, Chang FY, et al. The effect of ciprofloxacin in the prevention of bacte- rial infection in patients with cirrhosis after upper gastroin- testinal bleeding. Am J Gastroenterol. 1998;93:962-6.

Pauwels A, Mostefa-Kara N, Debenes B, Degoutte E, Lévy VG. Systemic antibiotic prophylaxis after gastrointestinal hemorrhage in cirrhotic patients with a high risk of infection. Hepatology. 1996;24:802-6.

Téllez-Ávila F, Sifuentes-Osornio J, Barbero-Becerra V, Franco-Guzmán A, Ruiz-Cordero R, Alfaro-Lara R, et al. Primary prophylaxis with ciprofloxacin in cirrhotic patients with ascites: a randomized, double blind study. Ann Hepatol. 2014;13(1):65-74.

Dupeyron C, Mangeney N, Sedrati L, Campillo B, Fouet P, Leluan G. Rapid emergence of quinolone resistance in cir- rhotic patients treated with norfloxacin to prevent spontaneous bacterial peritonitis. Antimicrob Agent Chemother. 1994;38:340-4.

Ortiz J, Vila MC, Soriano G, Miñana J, Gana J, Mirelis B, et al. Infections caused by Escherichia coli resistant to nor- floxacin in hospitalized cirrhotic patients. Hepatology. 1999;29:1064-9.

Fernández J, Ruiz del Arbol L, Gómez C, Durandez R, Serra- dilla R, Guarner C, et al. Norfloxa- cin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterol. 2006;131:1049-56.

Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila F, Soares-Wieser K, Mendez-Sanchez N, Gluud C, et al. Meta- analysis: antibiotic prohylaxis for cirrhotic patients with upper gastrointestinal bleeding e an updated Cochrane review. Aliment Pharmacol Ther. 2011;34:509e18.

Garcia-Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med. 2010;362:823e32.

Bernard B, Cadranel JF, Valla D, Escolano S, Jarlier V, Opolon P. Prognostic significance of bacterial infection in bleeding cirrhotic patients: a prospective study. Gastroenterology. 1995;108:1828e34.

Lee TH, Huang CT, Lin CC, Chung CS, Lin CK, Tsai KC. Similar rebleeding rate in 3-day and 7-day intravenous ceftriaxone prophylaxis for patients with acute variceal bleeding. J Formosan Med Assoc. 2016;115(7):547-52.

Fernández J, Del Arbol LR, Gómez C, Durandez R, Serradilla R, Guarner C, Planas R, Arroyo V, Navasa M. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology. 2006;131(4):1049-56.






Original Research Articles